Pharmaceuticals · SAN FRANCISCO, CA, United States
$7.98
+4.04% (+$0.31)2026-08-24
Smart-Money SignalNeutral · 46/100— Insiders are net sellers over 90 days (-$2K, 2 sales vs 1 buy)
Revenue-$1.5M
Net Income$12.0M
EPS$-0.80
Market Cap$32.3M
Price Performance
Historical data including institutional events
Company Profile
T
Thane Wettig
CEO & Executive Director
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
